Core Points - The company has received approval from the National Medical Products Administration for its absorbable composite bone repair material medical device, enhancing its product portfolio in the bone repair materials sector [1][2] - The product is classified as a Class III medical device with a registration certificate valid from September 25, 2025, to September 24, 2030 [1] - The new product builds on existing technology, incorporating absorbable polyester materials to improve strength and controllable degradation while maintaining excellent biocompatibility and bone healing capabilities [1] Company Impact - The approval of the new product is expected to broaden the company's range of offerings in the bone repair materials market, facilitating overall market expansion domestically [2] - The actual sales performance of the new product will depend on its competitive edge and market sales capabilities, making future operational performance difficult to predict [2]
证券代码:688613 证券简称:奥精医疗 公告编号:2025-054